NeoGenomics, Inc. (NEO): Price and Financial Metrics

NeoGenomics, Inc. (NEO): $8.61

-0.05 (-0.58%)

POWR Rating

Component Grades














  • Sentiment is the dimension where NEO ranks best; there it ranks ahead of 84.26% of US stocks.
  • NEO's strongest trending metric is Sentiment; it's been moving up over the last 177 days.
  • NEO ranks lowest in Value; there it ranks in the 13th percentile.

NEO Stock Summary

  • In terms of twelve month growth in earnings before interest and taxes, NEOGENOMICS INC is reporting a growth rate of -327.18%; that's higher than just 5.24% of US stocks.
  • As for revenue growth, note that NEO's revenue has grown 0.13% over the past 12 months; that beats the revenue growth of only 23.03% of US companies in our set.
  • The volatility of NEOGENOMICS INC's share price is greater than that of 93.94% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to NEOGENOMICS INC, a group of peers worth examining would be STIM, MLSS, AMRN, EVER, and APYX.
  • NEO's SEC filings can be seen here. And to visit NEOGENOMICS INC's official web site, go to

NEO Valuation Summary

  • In comparison to the median Healthcare stock, NEO's price/earnings ratio is 139.29% lower, now standing at -7.7.
  • NEO's price/sales ratio has moved down 19.1 over the prior 226 months.

Below are key valuation metrics over time for NEO.

Stock Date P/S P/B P/E EV/EBIT
NEO 2022-09-23 2.3 1.1 -7.7 -9.3
NEO 2022-09-22 2.3 1.1 -7.7 -9.4
NEO 2022-09-21 2.4 1.1 -7.9 -9.6
NEO 2022-09-20 2.4 1.1 -8.1 -9.8
NEO 2022-09-19 2.5 1.2 -8.4 -10.0
NEO 2022-09-16 2.6 1.2 -8.5 -10.1

NEO Growth Metrics

    Its 2 year price growth rate is now at -73.63%.
  • The 4 year cash and equivalents growth rate now stands at 198.1%.
  • The 3 year cash and equivalents growth rate now stands at 2218.27%.
Over the past 15 months, NEO's revenue has gone up $35,362,000.

The table below shows NEO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 489.313 -73.579 -146.818
2022-03-31 485.965 -57.973 -35.642
2021-12-31 484.329 -26.723 -8.347
2021-09-30 484.594 -0.962 48.828
2021-06-30 488.698 7.331 71.733
2021-03-31 453.951 10.603 -10.964

NEO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NEO has a Quality Grade of C, ranking ahead of 30.23% of graded US stocks.
  • NEO's asset turnover comes in at 0.366 -- ranking 397th of 561 Business Services stocks.
  • MSFT, VRNS, and SGRP are the stocks whose asset turnover ratios are most correlated with NEO.

The table below shows NEO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.366 0.422 0.085
2021-03-31 0.414 0.399 -0.033
2020-12-31 0.490 0.418 -0.014
2020-09-30 0.508 0.419 -0.033
2020-06-30 0.522 0.433 -0.042
2020-03-31 0.589 0.468 0.016

NEO Price Target

For more insight on analysts targets of NEO, see our NEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $56.80 Average Broker Recommendation 1.25 (Strong Buy)

NEO Stock Price Chart Interactive Chart >

Price chart for NEO

NEO Price/Volume Stats

Current price $8.61 52-week high $54.74
Prev. close $8.66 52-week low $6.85
Day low $8.60 Volume 965,200
Day high $9.06 Avg. volume 1,812,127
50-day MA $10.30 Dividend yield N/A
200-day MA $14.67 Market Cap 1.08B

NeoGenomics, Inc. (NEO) Company Bio

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.

NEO Latest News Stream

Event/Time News Detail
Loading, please wait...

NEO Latest Social Stream

Loading social stream, please wait...

View Full NEO Social Stream

Latest NEO News From Around the Web

Below are the latest news stories about NEOGENOMICS INC that investors may wish to consider to help them evaluate NEO as an investment opportunity.

NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022

NeoGenomics, Inc. (NASDAQ:NEO),a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announces that its liquid biopsy focused subsidiary Inivata Limited ("Inivata"), alongside collaborators, will present new data on its RaDaR™ assay for the detection of minimal residual disease (MRD) and recurrence at the European Society for Medical Oncology (ESMO) Congress, taking place September 9th-13th,

Yahoo | September 7, 2022

Needham downgrades NeoGenomics (NEO) to a Hold

E ratio of -9.37.

Carrie Williams on TipRanks | August 22, 2022

NeoGenomics Stock Is Downgraded. A ‘Turnaround Appears Daunting.’

A Wall Street bull finally threw in the towel on NeoGenomics stock. Needham’s Mike Matson, who rated the stock at Buy for more than a year and a half, flipped his rating to Hold, saying the shares are fairly valued and that he believes the pharma company’s turnaround efforts won’t pay off for several years. NeoGenomics stock fell 4% to $10.70 Monday.

Yahoo | August 22, 2022

NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, today announced, as required by the Nasdaq Listing Rules, equity inducement awards to Mr. Chris Smith, the company's new chief executive officer.

Yahoo | August 16, 2022

Company News for Aug 10, 2022

Companies in The News Are: NEO,H,ARMK,AHCO

Yahoo | August 10, 2022

Read More 'NEO' Stories Here

NEO Price Returns

1-mo -14.50%
3-mo 2.87%
6-mo -31.61%
1-year -82.24%
3-year -55.57%
5-year -22.64%
YTD -74.77%
2021 -36.63%
2020 84.07%
2019 131.96%
2018 42.33%
2017 3.38%

Continue Researching NEO

Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:

Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5589 seconds.